Abstract
During the past 5 years, better understanding of immunomodulatory and anti-angiogenesis properties of thalidomide has increased interest in the use of this agent for a wider variety of clinical applications. This article reviews the clinical evaluation of thalidomide for treatment or prevention of chronic graft-versus-host-disease.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Graft vs Host Disease / drug therapy*
-
Graft vs Host Disease / prevention & control*
-
Humans
-
Thalidomide / therapeutic use*
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Thalidomide